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Introduction
Creating and updating evidence-based guidelines in medi-
cine are costly and time-consuming. For that reason, the
nephrological community tried to build up a single set of
international guidelines under the aegis of Kidney Disease
Improving Global Outcomes (KDIGO) [1]. However, this
international effort may not be correctly perceived by Eu-
ropean nephrologists, who sometimes feel that differences
in practice patterns make it difficult to apply guidelines de-
veloped outside Europe. On the other hand, the latest ver-
sions of the European Best Practice Guidelines (EBPG)
may appear outdated in some respects, while not all as-
pects of nephrological practice are currently covered by
KDIGO.
A specially appointed ERA–EDTAWork Group met in
Paris to discuss a European guideline planning in early
January 2008, and agreed that the Association should con-
tinue producing and updating guidelines in collaboration
with KDIGO [2]. It also agreed that ERA–EDTA should
issue suggestions for clinical practice in areas in which ev-
idence is lacking or weak, which would be published as
‘clinical advice’ rather than ‘clinical guidelines’ [2].
With regard to peritoneal dialysis (PD), the European
Renal Best Practice (ERBP) Advisory Board recently de-
cided not to create new or updated guidelines, as there was
not enough new evidence to produce a meaningful change
in scope from the previous guidance documents published
in 2005 by EBPG [3]. Instead, it was felt that advice on
three important PD-related topics for everyday clinical
use was needed: peritoneal membrane evaluation, modality
selection and adequacy. The text on membrane evaluation
is currently in press [4].
The present publication comprises the clinical advice on
renal replacement therapy (RRT) modality selection for
end-stage renal disease (ESRD) patients. These recom-
mendations have been issued by an ERBP Expert Group
and approved by the ERBP Advisory Board.
Four areas of interest will be discussed:
(i) Initial dialysis modality selection
(ii) Choice between continuous ambulatory PD (CAPD)
and automated PD (APD)
(iii) Transition between RRT modalities
(iv) Assisted PD
1. Initial dialysis modality selection
Clinical advice 1.1:
There is insufficient evidence to support a general pref-
erence of HD over PD, or vice versa, for medical reasons.
Therefore, the initial modality choice should be made pri-
marily by the well-informed patient.
(i) As a consequence, all RRT centres should try and pro-
vide, or support in collaboration with other centres, all
available treatment options: PD (including CAPD and
APD), HD (including home HD and nocturnal pro-
grammes) and transplantation (including cadaveric
and non-cadaveric), to make sure that all patients
can select the modality that is most suitable for them.
(ii) As a consequence, all patients and their families
should receive well-balanced information about the
different RRT modalities, by means of a structured
education programme. This also applies to late-
referred patients and those starting dialysis in an
emergency situation, which should receive the infor-
mation once their condition has stabilized.
Most studies suggest a better survival rate in PD than in
HD patients during the first few years after starting therapy.
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The only randomized controlled trial on this subject sup-
ports this idea [5]. However, after 2 or 3years, outcome
on PD becomes equal to HD, or worse [6–9], depending
upon the study. These differences in outcome seem to be
attributable to differences in statistical approach, patient
mix and experience with the different modalities. Indeed,
outcomes on RRT, both in absolute terms and in relative
terms (PD vs HD), appear to be strongly influenced by
country and centre experience. Based on these findings,
the ERBP Expert Group suggests that the ‘PD first’ ap-
proach should be presented to the patient as the most log-
ical choice [10]. However, it also feels that there is not
enough hard evidence to consider starting with PD as com-
pulsory. Therefore, the patient’s preference should be taken
into account as the primary factor, since patient satisfac-
tion, compliance with therapy and quality of life are better
if the patient has been given the opportunity to make his/her
own informed choice. Actually, in most European
Countries and also at EU level, it is compulsory by law
to inform patients of all treatment modalities [11,12].
There is now accumulating evidence that the outcome of
patients treated in centres where only one modality is avail-
able, or where experience with alternative dialysis strategies
is limited, is jeopardized [13]. This seems reasonable as it
implies that, in those centres, patients are forced to the only
available RRToption, or are treated suboptimally by lack of
experience. All centres should make sure they provide, or at
least support in collaboration with another centre, all avail-
able modalities, including home HD. Although, for obvious
reasons, no data on randomized controlled trials are avail-
able on this topic, some recent well-conceived cohort stud-
ies have indicated that outcome of home (daily) HD is
superior to conventional in-centre dialysis, and even equal
to cadaveric transplantation, when differences in case mix
are taken into account [14]. Meanwhile for logistical rea-
sons, it may not be feasible for all centres to develop their
own freestanding home HD programme, and it is strongly
advised that centres organize such a programme jointly. In
such an agreement, care should be taken for a fair distribu-
tion of duties and benefits between centres, to avoid even-
tual economical bias hampering free patient selection for
home HD.
Also, the option of renal transplantation, both cadaveric
and non-cadaveric, should be discussed with the medically
suitable patients, as the outcomes of those patients appear
to be better after transplantation as compared to standard
haemodialysis [15]. However, for the elderly and for pa-
tients with multiple co-morbidities, this benefit is less clear
[16]. It should also not be neglected that there is shortage of
organs, and that it might be preferable, from a socio-ethical
viewpoint, to allocate organs to those patients who are ex-
pected to benefit the most from kidney transplantation.
Clinical advice 1.2:
The following conditions should not be considered as
contraindications to PD:
(i) Physical or mental inability to perform PD
(ii) Older age
(iii) Poor adherence/non-compliance to therapy
(iv) Obesity
(v) Congestive heart failure
(vi) Polycystic kidney disease
(vii) Diverticulosis
(viii) Abdominal hernias
(ix) Portal hypertension
(x) Liver transplantation
Performing PD requires a minimum of physical skills
and mental capacity. It is clear that some physical pro-
blems, such as visual impairment and tremor or deformi-
ties of the hands, may interfere with PD handling. In the
opinion of the ERBP Expert Group, these problems do not
a priori preclude the application of PD as an RRT. Several
companies and research groups have invested in the devel-
opment of tools to ease handling of the PD equipment
[17,18], and it is the task of the PD team to provide crea-
tive solutions to individual problems. Moreover, several
centres in the world have gained experience in the so-
called ‘assisted PD’ [19–21]. In this setting, it is not the
patient him/herself but a nurse or another assisting person
that performs the PD treatment. Assisted PD must be con-
sidered as an alternative to in-centre HD for non-autono-
mous patients. Even with the additional cost of the
assistance, assisted PD in developed countries has been re-
ported to be cheaper than in-centre HD [22] (for details,
see ‘Assisted PD’ section below).
There are an increasing number of elderly patients start-
ing dialysis worldwide. In Europe, in 2008, the population
older than 65 years accounted for 17% of the general pop-
ulation [23], and can be expected to continue to grow in
the future. When advising elderly patients on modality se-
lection, the following points should be considered [24]. On
one hand, elderly patients starting RRT have numerous co-
morbidities at dialysis initiation [25]. Older age is fre-
quently associated with loss of physical functions such
as strength, dexterity, vision or hearing. Furthermore, el-
derly patients may present cognitive dysfunction at dialysis
start. The initiation of dialysis can be associated with a sig-
nificant decline in the functional status [26,27], and also
cognitive function may deteriorate after dialysis initiation.
This implies that assistance may become necessary in self-
care patients during the course of their PD treatment. How-
ever, caregivers of elderly patients on PD may experience
adverse effects on their own quality of life [28], which
may, in turn, cause a loss of assistance. On the other hand,
PD may present some advantages in the elderly patients
with ESRD. Access failure rate is higher in the older HD
patients [29]. Elderly patients on dialysis are exposed to
arrhythmia and hypotension during the HD sessions. Qual-
ity of life is particularly relevant for the elderly patients on
dialysis. Travel time to and from the HD centre has a neg-
ative impact on patient’s quality of life [30,31], whereas
home therapy as offered by PD is associated with a better
quality of life compared with in-centre HD. In view of all
the above, non-dialytic (or so-called conservative) treat-
ment should also be discussed with the patient and his re-
latives. A projection of expected survival using the
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algorithm developed by Couchoud et al. [32] can be of
help to visualize the concept and consequences of dialytic
versus non-dialytic treatment. The ERBP Expert Group al-
so endorses the active use of advanced care directions, es-
pecially in the frail and elderly patients.
Presumed or real non-adherence to the prescribed PD
regimen can be a challenge to the PD team. Nevertheless,
it is unlikely that non-adherent PD patients will become
compliant HD patients. It is important for the caregiver,
particularly if there is a sudden change in adherence of
the patient, to try and find out why this happened. It is es-
pecially important to find out whether the non-compliance
is related to the PD therapy itself or whether it is a general
attitude of the patient. In some cases, the cause of non-
compliance is a condition that requires attention from the
caregiver, such as denial of disease, depression, social pro-
blems (like divorce or death of a beloved person), intercur-
rent illness and cognitive deterioration. Some of these
conditions are only temporary and/or can be treated ade-
quately. Some of the adherence problems may be solved
by the implementation of assisted PD [21].
There is currently not enough evidence to contraindicate
PD to obese individuals. However, several comments on
this issue are necessary. Obese patients, especially if dia-
betic, were shown to have increased risk of death after
starting on PD compared to HD [33,34]; however, such ev-
idence is scarce. Furthermore, most studies in PD patients
have found similar (if not better) survival in those who are
obese versus those with normal body mass index [35,36].
Obese patients may need larger dialysate volumes, usually
provided by APD, to achieve adequate Kt/V, although the
increase in body mass is not associated with a proportional
increase in body water volume [37–39]. However, PD may
not be the preferred dialysis modality or is relatively con-
traindicated in patients with morbid obesity [39,40], in
which there may be difficulties in peritoneal catheter
placement and tunnel healing process, increased risk of
pericatheter leak and infection, possible further weight
gain due to increased caloric absorption from the dialysate,
as well as a risk for abdominal pain or discomfort, and ag-
gravation of dyspnoea, gastro-oesophageal reflux, abdom-
inal hernias or vertebral disease, because of increased
intra-abdominal volume and pressure [38,39]. Use of ico-
dextrin solution may be considered for obese patients as
the body weight and fat mass in prospective studies have
been shown to be relative stable in patients using one ex-
change of icodextrin-based solution, compared to patients
using glucose-based solutions only [41–43].
Congestive heart failure (CHF) is increasingly common
in patients with ESRD. It is often associated with low
blood pressure, in spite of fluid overload, and it is one of
the frequent causes of haemodynamic instability during ul-
trafiltration to dry weight in HD patients. As such, PD,
with its more subtle and gentle capacity for ultrafiltration,
might be a better and more comfortable alternative. The
only large registry study comparing the outcome of pa-
tients with CHF on PD vs HD was undertaken in the
USA and found a higher mortality risk in PD patients
[7]. However, according to the ERBP Expert Group, the
results of this study cannot be extrapolated to European
patients, because of the different case mix and characteris-
tics of the US population, and since no icodextrin was
available to help maintain fluid balance in PD patients.
In addition, and maybe even more important, that study
had a methodological bias as it included only prevalent pa-
tients who survived the first 90 days on dialysis, a strategy
possibly inducing lead time bias in favour of HD. In addi-
tion, potential selection bias could not be accounted for in
this study. Many single-centre reports indicate that PD can
improve quality of life and New York Heart Association
(NYHA) classification in patients with CHF [44–46].
Based on the existing information, it is difficult to either
support or discard PD as a method of choice in CHF pa-
tients. One particular subgroup, however, could be that of
anuric PD patients with CHF, in which maintaining ade-
quate dry weight is quite difficult. Furthermore, clinically
unapparent overhydration could be present and significant
for the diminished cardiac reserve, and use of additional
objective measures for dry weight assessment (like bioim-
pedance, biomarkers or imagistic tools) is recommended.
Careful patient monitoring, control of water and salt in-
take, efforts to preserve peritoneal and renal function
and, in many cases, use of APD and icodextrin-based PD
solutions are critical for the management of these patients
[47]. However, if maintaining correct dry weight is still
impossible to achieve, patients should be promptly trans-
ferred to HD, preferably using slow-ultrafiltration, long-
hours techniques. The ERBP group acknowledges that
this is an important area for future research, in view of
the increasing frequency of these conditions, and the lack
of well-conceived trials on this topic.
2. Choice between CAPD and APD
Clinical advice 2.1:
There is as such no reason to prefer CAPD or APD, as
long as the dwell time of the patient is matched to his/her
peritoneal transport type. As outcomes on both modali-
ties have been found to be equal, choice should be guided
by patient preference.
Several studies [48–50] have observed that outcomes on
CAPD and APD are equal. However, it is important to
maintain the appropriate dwell time for the appropriate pa-
tient: short dwells for fast transporters, to avoid glucose
absorption and negative ultrafiltration, and long dwells
for slow transporters, to avoid sodium sieving [4]. Failing
to do so might lead to fluid overload and inadequate solute
removal. It is conceivable that short dwells can more easily
be obtained with the use of a cycler, whereas long dwells
seem to be more appropriate for CAPD. As a consequence,
it is not surprising to see that outcome of fast transporters
has been reported to be superior on APD, whereas out-
come of slow transporters was better on CAPD [51]. It
should be stressed, however, that, even with CAPD, short
dwells can be performed, and the APD treatment can be
expanded with an extra day exchange to achieve longer
dwell times. PD teams should try to accommodate the pa-
tient’s lifestyle issues with the underlying membrane char-
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acteristics, using the complete available armamentarium,
their experience and creativity.
3. Transition between modalities
While the first two sections of this publication deal with
the choice of RRT modality when a patient approaches
ESRD, the present item focuses on transition from one mo-
dality to another once the procurement of maintenance
RRT has been started. Three types of transition should
be considered: HD to PD, PD to HD, and failed renal trans-
plantation to either HD or PD.
One single modality may not procure adequate treat-
ment over an entire lifespan; therefore, nephrologists
sometimes have to recommend switching modalities dur-
ing the clinical course of ESRD patients. At any moment,
the consequences of each decision should be evaluated, to
estimate benefits or threats not only in the short term, but
also in the long term. Patients with chronic kidney disease
should be informed, before the start of their RRT, about the
possibility of being switched to an alternative modality lat-
er on during the course of their RRT. For that reason, un-
less there are absolute contraindications for a particular
modality, pre-dialysis information provided to patients
should cover all possible therapies, without hallmarking
options as ‘impossible’ or ‘bad’.
In the opinion of the ERBP Work Group, the patient’s
informed choice of treatment modality should be re-
spected, as long as his/her clinical conditions allow doing
so. If a chosen RRT modality later becomes inadequate,
transition to another therapy should be proposed, and the
underlying reasoning should be explained to the patient.
Even in these circumstances, the choice of the well-in-
formed patient should be respected. When patients decide
not to follow medical advice, despite obvious treatment
failure, it should be recorded that the change in treatment
has been recommended without success. The latter situa-
tion cannot be considered as inappropriate adherence to
the original modality by the treating physician.
3.1. Transition from HD to PD
In what follows, the ERBP Work Group describes some
conditions where the option of PD should be explained
to the patient as a potential alternative for HD, as this
treatment might be for some reason suboptimal.
Clinical advice 3.1:
Patients on HD should be informed about the option
of PD when they suffer from any the following clinical
conditions:
(i) Intradialytic haemodynamic intolerance and muscle
cramps despite optimal adjustment of dry weight
(ii) Problems to create a well-functioning native vascu-
lar access
(iii) Intractable or recurrent ascites
The rationale for considering PD in case of irremediable
haemodynamic intolerance of HD or incapacitating muscle
cramps is obvious [52–57]. In contrast to HD, PD is a con-
tinuous therapy that is not characterized by large volume
shifts or sudden changes in serum electrolytes like potas-
sium or calcium. Alternatively, short daily or nocturnal
HD, preferably performed at home, may also be consid-
ered, in order to improve haemodynamic stability.
Pre-dialysis counselling should include the information
to the patient on the importance of vascular access for HD,
the need for preservation of arm veins for placement of
vascular access and the notion that starting with PD is a
means of preserving the vascular potential. In HD patients,
where creation of a well-functioning native vascular access
is not possible, PD should be proposed as a better alterna-
tive than the use of permanent central vein catheters, which
are associated with substantial morbidity and mortality. In-
fection risk on PD is comparable to that of HD patients
with a native fistula, whereas the infection risk of a tun-
nelled HD catheter is twice as high.
Ascites may be due to heart failure, hepatic failure or
peritoneal metastases. While ultrafiltration during HD
may be able to remove fluid from the body and sometimes
alleviate the abdominal distension due to ascites, it will of-
ten fail to do so. PD may be a better alternative, since fluid
can be evacuated through the PD catheter [58,59]. The the-
oretical concerns of excessive loss of albumin or higher
infectious risk seem clinically irrelevant [59].
It has been demonstrated that the outcome of patients
transferred from HD is similar to that achieved in patients
who are kept on PD from the start of RRT on [60].
3.2. Transition from PD to HD
Clinical advice 3.2:
Patients on PD should be informed about the option
of HD when they suffer from any the following clinical
conditions:
(i) Incapacity to maintain fluid balance
(ii) Relapsing or persistent peritonitis
(iii) Incapacity to control uraemic symptoms or to main-
tain a good nutritional state
(iv) Changes in lifestyle circumstances
(v) Declining residual renal function
(vi) Intra-abdominal surgery
(vii) Sclerosing peritonitis
Euvolaemia is an important predictor of outcome in PD
patients [61–63]. Volume overload is related to cardiac
dysfunction [64,65] and mortality [66]. Guidance on
how to achieve and maintain euvolaemia in individual
PD patients is hampered by two factors: (i) the absence
of a convenient and accurate device with which to mea-
sure volume status; (ii) lack of insight in the prevalence
of and factors associated with volume overload. Volume
overload in PD can have several causes, which can be
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even present together in the same patient at the same
time. The most common causes are inadequate dietary in-
take of salt and/or water, and ultrafiltration failure. En-
hanced peritoneal transport via small pores with rapid
dissipation of the osmotic gradient (fast-transporter status)
is a common cause, which can be readily diagnosed by
performing a validated membrane permeability test, and
therapy can be adapted accordingly, as described in the
EBPG guidelines on this issue [67]. Other causes of ultra-
filtration failure, such as decreased osmotic conductance,
enhanced fluid absorption or increased intra-abdominal
pressure can be diagnosed by studying sodium sieving, dis-
appearance rate of dextrans from the peritoneal cavity, or
intra-abdominal pressure measurement, respectively [68].
Most episodes of peritonitis, exit-site infection or tunnel
infection can be treated successfully with intraperitoneal
antibiotics and should not be a reason to transfer patients
to HD. There are some exceptions to this general rule,
however. Exit-site or tunnel infections progressing to or ac-
companied by peritonitis (i.e. catheter-related peritonitis)
with the same organism often require catheter removal. Re-
fractory peritonitis (defined as failure to clear the peritone-
al effluent from infectious organisms after more than
5 days of appropriate antibiotics) and relapsing peritonitis
(defined as a new peritonitis episode with same organism
within 4 weeks from the previous episode) commonly re-
quire catheter removal in order to resolve the problems.
Also, catheter removal is needed in fungal peritonitis and
in unresponsive cases of peritonitis with mycobacteria or
multiple enteric microorganisms [69]. Catheter removal
in these cases requires a period of peritoneal rest before
insertion of a new catheter (2weeks at least, 6weeks in
case of mycobacterial peritonitis). This, of course, requires
temporary transition to HD, unless residual renal function
is still satisfactory. Peritoneal adhesions or changes in
membrane characteristics may be a consequence of persis-
tent peritonitis and impede further continuation of PD.
Since it is difficult to predict their occurrence and implica-
tions, the ERBP Work Group feels that insertion of a new
PD catheter and resuming PD treatment should be consid-
ered if the patient desires to stay on PD. It should also be
kept in mind that persisting or relapsing peritonitis could
be a hallmark of poor peritoneal membrane condition,
making maintenance of PD risky. Patients should be
warned that, in these circumstances, successful PD contin-
uation is uncertain, and that transfer to HD might still be
needed some time later [70]. Reinsertion of a new catheter
should preferably be done under laparoscopy, in order to
visualize and—if necessary—treat adhesions.
The importance of residual renal function (RRF) as a
determinant of PD patients’ outcome has been demon-
strated by numerous studies [71–73]. The PD community
started focusing on this finding since some of the larger
trials on PD adequacy failed to show further improve-
ment of outcome by increasing peritoneal small solute
clearances [74,75]. The benefits of RRF have been attrib-
uted to its role in the maintenance of fluid balance, its
association with lower inflammation and better nutritional
status, its endocrine functions (erythropoietin production
and alpha-hydroxylation of vitamin D) and its contribu-
tion to the removal of toxic substances [76–82]. Based
on these data, some have argued that PD patients should
be switched to HD in case of a complete loss of RRF;
however, it is quite likely that, also in HD patients,
RRF is an important predictor of outcome. In addition,
several observational studies have demonstrated that PD
in anuric patients is feasible, with acceptable outcomes
[61,75,83]. Special attention has to be paid, however, to
the volume status of these patients. Given the importance
of RRF for outcome, maximum efforts should be done to
preserve it, by avoiding nephrotoxic insults. The use of
angiotensin-converting enzyme (ACE) inhibitors [84]
and angiotensin receptor blockers [85] has been shown
to have a protective impact on RRF.
Surgical procedures can disturb the integrity of the
peritoneal membrane, leading to leakage or insufficient
remaining surface area. However, some surgical proce-
dures (e.g. nephrectomy or removal of a non-functional
renal graft) can be performed without disrupting the peri-
toneal membrane. It is recommended to inform the sur-
geons about the importance of preserving peritoneal
membrane integrity, and to carefully consider surgical in-
dications to avoid iatrogenic disruption of the peritoneal
membrane.
Some nephrologists advocate ‘pre-emptive’ switching of
PD patients to HD after 2 or 3 years from PD start, even
when every aspect of the treatment is going well. This rec-
ommendation is based on the findings that, after a few
years, outcome on PD starts to get worse than on HD
[6–9], and on the concepts that PD may become inade-
quate with declining RRF and/or that the incidence of
sclerosing peritonitis starts to rise with time spent on
PD. The ERBP Expert Group endorses here the recom-
mendation of the International Society for Peritoneal Dial-
ysis that time on PD alone should not be a decisive factor
in itself for transferring patients from PD to HD [86].
However, with an increasing vintage on PD, physicians
should be increasingly aware of the potential pitfalls of
the technique, and discuss these and the possible alterna-
tives with the patient.
3.3. Choice of dialysis modality for patients with
failed renal transplantation
Clinical advice 3.3:
In patients with failed renal transplantation who return
to dialysis, there is no proven difference in survival be-
tween HD and PD. Therefore, the choice of dialysis mo-
dality for these patients should be based on the same
principles as those applying to the initial modality choice.
There is little data available on the impact of dialysis
modality on the outcome of patients with failed kidney
transplant. However, PD seems to be underused in this set-
ting, for several probable reasons: (i) in most dialysis cen-
tres, HD is predominant over PD; (ii) the start of dialysis in
emergency situations also favours HD; (iii) the fear of in-
creased peritonitis rate or of rapid loss of RRF in patients
transferred to PD [87].
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Sasal et al. [88] reported higher morbidity and mortality
rates in patients starting PD after transplant failure com-
pared to de novo PD patients. On the other hand, Davies
[89] showed that there is no significant difference in sur-
vival between these two categories of PD patients after cor-
rection for age and co-morbidity. Furthermore, other
studies found similar rates of peritonitis, renal and perito-
neal clearances decline [90], and technique failure [91] in
both transplanted and non-transplanted PD subjects. More
importantly, however, comparative studies (which are
scarce and retrospective in nature) found no differences
in survival of patients with failed renal transplantation on
HD versus PD [92,93].
The issue of tapering immunosuppression or not after
restarting PD is still a matter of controversy, since there
is no evidence of the beneficial effects of preserving resid-
ual graft function (similar to non-transplanted patients).
On the other hand, the continuation of immunosuppressive
therapy implies an increased risk of infections and malig-
nancies [90]. Therefore, the decision is currently based on
purely empirical considerations. Slow reduction of immu-
nosuppressive drugs is probably preferable, as it was
shown to be associated with similar RRF after 1 year on
PD as in non-transplanted patients, without increasing
the risk of peritonitis [92].
4. Assisted PD
4.1. Definition of assisted PD
Assisted PD can be defined as a PD modality performed
at the patient’s home with the assistance of a health-care
technician, a community nurse, a family member or a
partner. Additional funding is necessary when patients
are assisted by a nurse or by a health-care assistant.
Therefore, when using the term ‘assisted PD’, information
regarding the type of assistance must be provided. There
are two modalities of assisted PD: assisted APD and as-
sisted CAPD. Assisted PD must be considered as an alter-
native to in-centre HD for non-autonomous patients.
4.2. The assisted PD programme
Even with the additional cost of the assistance, assisted PD
in developed countries is reported to be cheaper than in-cen-
tre HD [22], although costs may vary between countries. As-
sisted PD enables nephrologists to increase the use of PD in
incident dialysis patients [93]. Community-based nurses
must be trained by nurses from the PD centre to perform
the connection and the exit-site dressing, and to set up the
cycler in case of assisted APD. A 24-h ‘hot line’ to provide
medical or nursing counselling to those involved in the pa-
tient’s care is needed. The PD centre must dealwith organiz-
ing the patient follow-up in the PD clinic and hospitalization
in the nephrology unit whenever necessary. For assisted
APD, only two interventions at the patient’s home are nec-
essary [94,95], whereas patients on assisted CAPD need
four visits daily. In countries where assisted PD is fully cov-
ered by the health-care insurance, most of the patients on
assisted PD are treated by assisted CAPD [96,97]; patients’
cognitive dysfunction and/or anxiety linked to the cycler
therapy may explain this preference. In order to decrease
the time spent by nurses at the patient’s home, a non-discon-
nectable device with ultraviolet flash can be used. Patients
on assisted PD must be reassessed regularly to see whether
or not they have become competent to perform self-care PD.
For patients on assisted APD, family assistance is associated
with a lower peritonitis risks compared with nurse assis-
tance [98]. However, the results are equivalent when centres
send one of their PD nurses for a visit at the patient’s home
on a regular basis; this emphasizes the fact that nurses in
charge of assisted PD patients must be trained and re-trained
by the nurses from the PD centre. In elderly patients, as-
sisted CAPD is not associated with greater peritonitis risk
compared with the family-assisted CAPD [99].
4.3. Indications of assisted PD
Nurse- or health-care technician-assisted PD is indicated
for ESRD patients who choose PD as RRT modality or
in whom HD is contraindicated, who have no contraindi-
cation to PD, but are incapable to perform PD exchanges
by themselves, and whose family members’ quality of life
is affected by the burden of caregiving.
Assisted PD can be indicated in incident dialysis pa-
tients or in previously self-care PD patients who have lost
their autonomy.
4.4. Assisted PD for the unplanned dialysis starter
The unplanned dialysis starter can be defined as a patient
who starts dialysis without any vascular access or PD cath-
eter. These patients usually start HD through a venous
catheter. Recently, strategies to use PD for unplanned dial-
ysis starters were implemented [21,100,101]. Assisted PD
can be used for a short period of time pending patient ed-
ucation [21,101].
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